14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OKUR vs ASMB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, OnKure Therapeutics, Inc. (OKUR) captures the overall head-to-head institutional edge over Assembly Biosciences, Inc (ASMB) on higher Unified Composite conviction (36.0/100 SELL vs. 30.4/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while ASMB wins 4–2 across the 6-pillar growth and valuation breakdown. OKUR trades at $2.70 (N/M Forward P/E, 0.0% operating margin) versus ASMB at $22.19 (N/M Forward P/E, -31.8% operating margin).
Growth vs. Quality Trade-Off: OKUR earns the overall head-to-head edge with a stronger Unified Composite Score (36.0/100 SELL vs. ASMB 30.4/100 SELL) and 0.96β · 100% Vol risk profile, whereas ASMB leads top-line expansion (-72.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although OKUR compares more favorably head-to-head, both OKUR (36.0/100 SELL) and ASMB (30.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs ASMB. Trailing 12-month operating profitability (OKUR 0.0% vs ASMB -31.8%) and valuation multiples (OKUR N/M vs ASMB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $460.7M market capitalization and -31.8% operating margin.
OpEx & R&D Reinvestment31.4% of Rev ($21M)
90D Engineering Disclosures0 Published
Investor FAQ OKUR vs ASMB Key Questions & Quantitative Answers
As of Nov 20, 2026, OnKure Therapeutics, Inc. (OKUR) captures the overall head-to-head institutional edge over Assembly Biosciences, Inc (ASMB) on higher Unified Composite conviction (36.0/100 SELL vs. 30.4/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while ASMB wins 4–2 across the 6-pillar growth and valuation breakdown. OKUR trades at $2.70 (N/M Forward P/E, 0.0% operating margin) versus ASMB at $22.19 (N/M Forward P/E, -31.8% operating margin). Growth vs. Quality Trade-Off: OKUR earns the overall head-to-head edge with a stronger Unified Composite Score (36.0/100 SELL vs. ASMB 30.4/100 SELL) and 0.96β · 100% Vol risk profile, whereas ASMB leads top-line expansion (-72.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OKUR compares more favorably head-to-head, both OKUR (36.0/100 SELL) and ASMB (30.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ASMB leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ASMB at -72.6% YoY revenue growth and +0.0% YoY earnings growth on $67M TTM revenue (-0.4% gross margin, -31.8% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $67M for ASMB. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus 31.4% of Rev ($21M) (0 disclosures) for ASMB.
ASMB screens cheaper on headline valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ASMB trades at N/M Forward P/E, 30.0x Trailing P/E, N/M PEG, and 6.9x EV/Revenue (-31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus ASMB (-4.6% ROE) capital efficiency.
In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, ASMB carries 109.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 57% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.